Expression of CD200 in acute myeloid leukemia stem cells and its correlation with clinical efficacy

doi:10.3877/cma.j.issn.1674-6880.2018.01.006

Abstract

Abstract:

Objective

To investigate the expression of CD200 in leukemia stem cells (LSCs) from the patients with acute myeloid leukemia (AML) and its correlation with clinical efficacy.

Methods

A total of 137 AML patients admitted to Quzhou People's Hospital from April 2014 to April 2017 were collected and divided into M1-M5 types, according to AML classification. Based on the clinical efficacy, AML patients were also statistically divided into three groups: complete remission (CR) group (n=59), partial remission (PR) group (n=47) and non-remission (NR) group (n=31). The flow cytometry was used for separating bone marrow LSCs and detecting the expressions of LSCs and CD200 in LSCs before and after treatment.

Results

24.82% (34/137) AML patients had CD200 expression in LSCs, while the positive proportions of CD200 expression in each subtype of AML were significantly different (5/11, 13/26, 4/35, 3/22, 9/43; χ²=16.533, P=0.002). AML-LSCs had high expressions in all AML subtypes, which showed no significant difference (F=0.980, P=0.421); except that the expression of CD200 in the LSCs was obviously lower in the M3 group [(10.1 + 2.7)%], the CD200 expressions were no difference in the other AML subtypes [(16.5 ± 2.8)%, (19.7 ± 4.0)%, (16.4 ± 2.4)%, (17.0 ± 3.1)%, all P > 0.05]. The treatment effect observation showed that the expressions of CD200 in the LSCs were not statistically significantly different among CR, PR and NR groups before treatment (all P > 0.05); the expression of CD200 in the LSCs decreased with the improvement of symptoms after treatment [(16.4 ± 3.6)%, (10.8 ± 2.6)%, (5.0 ± 1.8)%, all P < 0.05]. There was a significant difference of CD200 positive expression between CR and NR groups after treatment (5/59 vs. 14/31, P < 0.017); in addition, the comparison of CD200⁺/CD200^- in CR, PR, NR subgroups of AML M3 group was significantly different (0/22, 1/11, 1/0; χ²=17.786, P < 0.001).

Conclusion

The high expression of CD200 in LSCs of AML patients has a certain relationship with poor prognosis, which can affect the clinical efficacy.

Key words: Leukemia, myeloid, acute, CD200, Clinical efficacy

Xiaoyan Zheng, Chaoqi He, Fangjian Chen, Hui Huang, Fenzhi Wu, Bicui Zhan. Expression of CD200 in acute myeloid leukemia stem cells and its correlation with clinical efficacy[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2018, 11(01): 35-40.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwzzyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6880.2018.01.006

https://zhwzzyxzz.cma-cmc.com.cn/EN/Y2018/V11/I01/35

Figures/Tables 3

References 21

[1]	Jentzsch M, Bill M, Nicolet D, et al. Prognostic im-pact of the CD34⁺/CD38^- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation[J]. Am J Hematol, 2017, 92 (4): 388-396.
[2]	饶若，王述文，姚红霞，等. CD133两种亚型分子在急性白血病中的表达及意义[J].免疫学杂志，2017，33（3）：273-276.
[3]	Jiang Y, Xu P, Yao D, et al. CD33, CD96 and death associated protein kinase (DAPK) expression are associated with the survival rate and/or response to the chemotherapy in the patients with acute myeloid leukemia (AML) [J]. Med Sci Monit, 2017 (23): 1725-1732.
[4]	Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503) [J]. Leukemia, 2017, 31 (1): 34-39.
[5]	Koller E. Acute myeloid leukemia: highlights from the 54th ASH meeting held in Atlanta, Georgia[J]. Memo, 2013, 6 (3): 185-188.
[6]	Blair A, Hogge DE, Sutherland HJ. Most acute mye-loid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34⁽⁺⁾/CD71^(-)/HLA-DR^-[J]. Blood, 1998, 92 (11): 4325-4335.
[7]	Blair A, Hogge DE, Ailles LE, et al. Lack of expre-ssion of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo[J]. Blood, 1997, 89 (9): 3104-3112.
[8]	Blair A, Sutherland HJ. Primitive acute myeloid leuk-emia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117)[J]. Exp Hematol, 2000, 28 (28): 660-671.
[9]	Jordan CT, Upchurch D, Szilvassy SJ, et al. The in-terleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells[J]. Leukemia, 2000, 14 (10): 1777-1784.
[10]	Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J]. Nature, 1994, 367 (6464): 645-648.
[11]	Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med, 1997, 3 (7): 730-737.
[12]	Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells[J]. Leukemia, 2002, 16 (4): 559-562.
[13]	Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[J]. Blood,2001, 98 (8): 2301-2307.
[14]	Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion[J]. Trends Immunol, 2008, 29 (10): 464-468.
[15]	Gorczynski R, Chen Z, Kai Y, et al. CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules[J]. J Immunol, 2004, 172 (12): 7744-7749.
[16]	Lauzon-Joset JF, Langlois A, Lai LJ, et al. Lung CD200 receptor activation abrogates airway hyperresponsiveness in experimental asthma[J]. Am J Respir Cell Mol Biol, 2015, 53 (2): 276-284.
[17]	Alapat D, Coviello-Malle J, Owens R, et al. Dia-gnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma[J]. Am J Clin Pathol, 2012, 137 (1): 93-100.
[18]	Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia[J]. Leukemia, 2007, 21 (3): 566-568.
[19]	Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma[J]. Blood, 2006, 108 (13): 4194-4197.
[20]	顾宝罗，赵洪灿，范剑，等. CD47在急性髓细胞白血病干细胞中表达的临床意义[J/CD].中华危重症医学杂志（电子版），2013，6（4）：16-19.
[21]	胡蓓莉，张隽瑜，贺超奇，等.急性髓样白血病患者骨髓干细胞CD200的表达及与临床疗效的关系[J/CD].中华危重症医学杂志（电子版），2017，10（3）：165-171.

AML亚型组	例数	CD200阳性表达占比	AML-LSCs表达水平（%）	CD200在LSCs中表达水平（%）
M1组	11	5/11	78 ± 16	16.5 ± 2.8^b
M2组	26	13/26^a	80 ± 20	19.7 ± 4.0^b
M3组	35	4/35	73 ± 18	10.1 ± 2.7
M4组	22	3/22	83 ± 23	16.4 ± 2.4^b
M5组	43	9/43	80 ± 18	17.0 ± 3.1^b
χ²/F值	?	16.533	0.980	5.001
P值	?	0.002	0.421	0.003

AML亚型组	例数	CD200阳性表达占比	AML-LSCs表达水平（%）	CD200在LSCs中表达水平（%）
M1组	11	5/11	78 ± 16	16.5 ± 2.8^b
M2组	26	13/26^a	80 ± 20	19.7 ± 4.0^b
M3组	35	4/35	73 ± 18	10.1 ± 2.7
M4组	22	3/22	83 ± 23	16.4 ± 2.4^b
M5组	43	9/43	80 ± 18	17.0 ± 3.1^b
χ²/F值	?	16.533	0.980	5.001
P值	?	0.002	0.421	0.003

疗效分组	例数	CD200在LSCs中的表达水平（%）
疗效分组	例数	治疗前	治疗后
CR组	59	13.8 ± 1.9^a	5.0 ± 1.8
PR组	47	16.0 ± 2.5^b	10.8 ± 2.6^a
NR组	31	16.8 ± 3.8	16.4 ± 3.6^ab
F值	?	15.750
P值	?	< 0.001

疗效分组	例数	CD200在LSCs中的表达水平（%）
疗效分组	例数	治疗前	治疗后
CR组	59	13.8 ± 1.9^a	5.0 ± 1.8
PR组	47	16.0 ± 2.5^b	10.8 ± 2.6^a
NR组	31	16.8 ± 3.8	16.4 ± 3.6^ab
F值	?	15.750
P值	?	< 0.001

疗效分组	例数	AML亚型组
疗效分组	例数	M1组	M2组	M3组	M4组	M5组
CR组	59	1/4	2/9	0/22	1/9	1/10
PR组	47	1/3	2/5	1/11	1/5	6/12
NR组	31	1/1	4/4	1/0	2/4	6/8
χ²值	?	0.665	2.223	17.786	1.385	3.471
P值	?	0.717	0.329	< 0.001	0.500	0.176

Please choose a citation manager

Content to export